Versant Ventures V, LLC - 20 Jul 2023 Form 3 Insider Report for Turnstone Biologics Corp. (TSBX)

Role: 10%+ Owner
Signature: Versant Ventures V, LLC, By /s/ Max Eisenberg, Chief Operating Officer
Issuer symbol: TSBX
Transactions as of: 20 Jul 2023
Transactions value $: $0
Form type: 3
Filing time: 20 Jul 2023, 21:46:03 UTC
Previous filing: 07 Jun 2022
Next filing: 27 Jul 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TSBX	Series A Preferred Stock							20 Jul 2023	Common Stock	988,832		By Versant Venture Capital V, L.P.	F1, F2
holding	TSBX	Series A Preferred Stock							20 Jul 2023	Common Stock	75,255		By Versant Venture Capital V (Canada) LP	F1, F3
holding	TSBX	Series A Preferred Stock							20 Jul 2023	Common Stock	32,971		By Versant Ophthalmic Affiliates Fund I, L.P.	F1, F4
holding	TSBX	Series A Preferred Stock							20 Jul 2023	Common Stock	29,744		By Versant Affiliates Fund V, L.P.	F1, F5
holding	TSBX	Series B-1 Preferred Stock							20 Jul 2023	Common Stock	442,055		By Versant Venture Capital V, L.P.	F1, F2
holding	TSBX	Series B-1 Preferred Stock							20 Jul 2023	Common Stock	33,642		By Versant Venture Capital V (Canada) LP	F1, F3
holding	TSBX	Series B-1 Preferred Stock							20 Jul 2023	Common Stock	14,739		By Versant Ophthalmic Affiliates Fund I, L.P.	F1, F4
holding	TSBX	Series B-1 Preferred Stock							20 Jul 2023	Common Stock	13,297		By Versant Affiliates Fund V, L.P.	F1, F5
holding	TSBX	Series B-2 Preferred Stock							20 Jul 2023	Common Stock	957,787		By Versant Venture Capital V, L.P.	F1, F2
holding	TSBX	Series B-2 Preferred Stock							20 Jul 2023	Common Stock	72,892		By Versant Venture Capital V (Canada) LP	F1, F3
holding	TSBX	Series B-2 Preferred Stock							20 Jul 2023	Common Stock	31,936		By Versant Ophthalmic Affiliates Fund I, L.P.	F1, F4
holding	TSBX	Series B-2 Preferred Stock							20 Jul 2023	Common Stock	28,810		By Versant Affiliates Fund V, L.P.	F1, F5
holding	TSBX	Series C Preferred Stock							20 Jul 2023	Common Stock	140,190		By Versant Venture Capital V, L.P.	F1, F2
holding	TSBX	Series C Preferred Stock							20 Jul 2023	Common Stock	10,669		By Versant Venture Capital V (Canada) LP	F1, F3
holding	TSBX	Series C Preferred Stock							20 Jul 2023	Common Stock	4,667		By Versant Ophthalmic Affiliates Fund I, L.P.	F1, F4
holding	TSBX	Series C Preferred Stock							20 Jul 2023	Common Stock	4,216		By Versant Affiliates Fund V, L.P.	F1, F5
holding	TSBX	Series D Preferred Stock							20 Jul 2023	Common Stock	274,990		By Versant Vantage II, L.P.	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock will automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
F2	Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F3	Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Jerel C. Davis is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F4	Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F5	Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Affiliates, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F6	Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. Jerel C. Davis is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.